Aimmune Therapeutics is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. Co.'s main therapeutic approach, which it refers to as Characterized Oral Desensitized Immunology Therapy (CODIT), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure or reduce symptom severity should an allergic reaction occur. PALFORZIA (Peanut (Arachis hypogaea) Allergen Powder-dnfp) is Co.'s internally developed product utilizing CODIT and has been approved by the U.S. Food and Drug Administration and it is indicated for the mitigation of allergic reactions.
|
Free AIMT Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.67 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: AIMT Stock Forecast Based on Zacks ABR data; powered by Xignite |